HIFU does not involve surgery but instead uses a High Intensity Focused Ultrasound (HIFU) beam which safely and effectively heats and destroys pathogenic tissue rapidly with minimal side effects.
HIFU PROSTATE PROCEDURE SHOWS LIMITED SIDE EFFECTS In April 2012 in a research study 42 patients received focal HIFU therapy delivered to clinically significant cancer lesions using the Sonablate 500 developed by US HIFU.
The results showed that urinary and erectile function returned to pre- treatment levels 12 months after treatment. None of the men who completed the trial had urine leak and just one in ten suffered from poor erections. Cancer control was encouraging although this was not the primary aim of the study. No biopsy evidence of cancer was identified in the treated regions in 30 of 39 men who were biopsied at six months and 36 of the 39 were free of clinically significant cancer. After re-treatment in four men, a total of 39 patients had no imaging evidence of disease at 12 months.
USHIFU is a privately held, venture- backed healthcare company. US HIFU is committed to treating prostate cancer using HIFU with the Sonablate 500, a minimally invasive, outpatient procedure.
Currently, the device is not approved in the US but it is available for the treatment of prostate cancer in more than 30 countries.
HIFU (HIGH INTENSITY FOCUSED ULTRASOUND) EQUIPMENTS Sonalleve MR-HIFU Fibroid Therapy system by Philips which offers a non- invasive alternative to the traditional surgical treatments for uterine fibroids in women.
Exablate 2000 by Insightec for uterine fibroids;
Sonablate by Focus for prostate cancer on trial in US, approved elsewhere;
Ablatherm by EDAP-TMS for prostate cancer on trial in US, approved elsewhere;
OTHER DEVELOPMENTS Insurance Claims Filing Services (ICFS – www.icfstx.com) specializes in assisting US citizens with filing insurance when care has been received internationally. They have had some success in securing reimbursement for a number of HIFU patients for procedures done outside the country.